Ivermectin for Stage IV Cancer
Also known as: Stromectol
A Nobel Prize-winning antiparasitic with multiple anti-cancer mechanisms including P-glycoprotein modulation to reverse multidrug resistance.
Mechanism of Action
Ivermectin modulates chloride ion channels, inhibits PAK1 kinase activity, blocks Wnt/β-catenin signaling, and induces mitochondrial dysfunction in cancer cells. Critically, it modulates P-glycoprotein, potentially reversing multidrug resistance in chemotherapy-resistant tumors. It also inhibits cancer stem cell self-renewal.
General mechanism: Macrocyclic lactone. Chloride channel modulation, PAK1 inhibition, Wnt blockade, P-glycoprotein modulation.
Current Evidence
Preclinical evidence across multiple cancer types including breast, ovarian, glioblastoma, and leukemia. Its P-glycoprotein modulation could sensitize resistant tumors to standard chemotherapy. Small clinical studies are underway.
Clinical Status: FDA-approved antiparasitic. Cancer repurposing in early clinical investigation. Available and inexpensive globally.
Safety Profile
Well-established safety profile from decades of antiparasitic use. Neurotoxicity risk in patients with BBB disruption. Generally safe at standard doses.
Key Research Questions
- Can ivermectin reverse multidrug resistance in chemotherapy-refractory cancers?
- What is the synergy with checkpoint inhibitors through immune modulation?
- Does ivermectin target cancer stem cells more effectively than bulk tumor cells?
Frequently Asked Questions
Is ivermectin being studied for cancer?
Yes. Ivermectin has shown anti-cancer activity in preclinical studies through multiple mechanisms: WNT/TCF pathway inhibition, chloride channel activation, PAK1 kinase inhibition, and immunogenic cell death induction. Clinical cancer trials are limited but emerging.
Ivermectin mechanism of action for cancer
Ivermectin targets cancer cells through: 1) Inhibiting WNT-TCF signaling in colorectal cancer, 2) Inducing immunogenic cell death via calreticulin exposure, 3) Inhibiting PAK1 kinase in multiple tumor types, 4) Activating chloride channels causing osmotic stress, 5) Enhancing chemosensitivity through P-glycoprotein modulation.